Introduction: The use of hysteroscopic laser ablation for intrauterine diseases is a new technology. This study aimed to evaluate the efficacy and safety of a novel 450-nm wavelength laser system for hysteroscopic resection of endometrial polyps. Methods: This retrospective study included 49 patients with suspected endometrial polyps treated at the Department of Obstetrics and Gynecology, the Second Affiliated Hospital of Xi’an Jiaotong University, between October 2022 and November 2023. The participants were allocated into two groups: the blue laser group (n=24) and the control group, which underwent traditional hysteroscopic resection (n=25). Results: At baseline, no statistically significant differences were observed between the two groups. Both groups achieved a 100% success rate in terms of cutting and hemostatic efficiency for endometrial polyps. The operation time for the blue laser group was marginally shorter than that for the electric resection group (6.63 minutes vs. 7.96 minutes, P=0.213), and the change in hemoglobin level was slightly lower in the blue laser group than in the electric resection group (7.96 g/L vs. 10.4 g/L, P=0.643); however, these differences were not statistically significant. Additionally, there were no significant differences between the two groups in terms of the rate of secondary cervical dilation, length of hospital stay, postoperative complications, or surgeon satisfaction with the surgical system. Conclusion: Our preliminary findings suggest that blue laser hysteroscopic endometrial polypectomy is both effective and safe. Nonetheless, to comprehensively assess the long-term effects and potential benefits of this novel technology, larger randomized controlled trials are warranted.
Gong et al. (Sun,) studied this question.